Korro’s $116m Series B Round Will Advance Pipeline Beyond AATP

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Hoping to bring a candidate for the alpha-1 disorder into the clinic in 2023, Korro’s latest funding is meant to enable development of a rare CNS disorder drug and a third drug for a more prevalent indication.

Macro photo of tooth wheel mechanism with FUNDING concept words
RNA-editing focused Korro adds $116m to its prior $90m raise

Korro Bio, Inc. is adding $116m in series B funding to enable the expansion of its pipeline of RNA-editing therapies beyond its lead preclinical program in alpha-1 antitrypsin deficiency (AATP). After announcing the investment led by Eventide Asset Management on 5 January, Korro’s CEO Ram Aiyar told Scrip that he believes RNA editing offers potential in a wide range of therapeutic spaces and that he wants to de-risk the biotech’s R&D prospects with multiple programs.

“I'm an engineer by training; I hate risk,” he said. “The best thing I know to do is to mitigate...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.